Epioxa Corneal Crosslinking

At ASCRS, Dr. Ken Beckman walked through the epi-on crosslinking data and one detail is hard to ignore: in younger patients, the sham arm steepened by 1.3D in just 6 months. That’s not slow progression. That’s aggressive. It really shifts how you think about timing, waiting may not be the safest option in this group. And then looking longer term… by 30 months, treated eyes were still flattening (1.7D), not just holding steady. So this isn’t just stabilization. It’s a continued effect over time. #ASCRS2026 Dr. Ken Beckman has financial disclosures with Glaukos References: Beckman KA et al. Persistence of Epithelium-on Corneal Collagen Crosslinking Treatment Effect in Patients with Keratoconus. Poster presented at the ASCRS Annual Meeting, Washington, DC, 2026. Additional data discussed during EW-I: Introducing Epioxa, EyeWorld Corporate Event, ASCRS 2026.